Jiangsu Biodals Life Science Announces Shanghai Launch of VASOLINE® Artificial Vascular Graft and Files IPO Prospectus

According to 2022 statistics from the National Health Commission, the number of hypertensive patients in China has approached 300 million, with a continuing upward trend. Hypertension is a major risk factor for aortic dissection; as the number of individuals with hypertension continues to rise, the incidence of aortic dissection has also increased.

Aortic dissection is caused by various pathological factors that lead to tearing of the aortic intima, which gradually separates under the impact of blood flow, forming a "false lumen" within the aortic vessel cavity. If the separation is too severe or the pressure within the "false lumen" becomes excessively high, it can cause aneurysmal dilation of the aortic adventitia. Once formed, aortic dissection affects blood supply to vital organs throughout the body, such as the heart and brain, making it a significant cause of patient mortality.

Clinically, aortic dissection is commonly classified into Stanford type A and Stanford type B based on the location of the primary intimal tear and the extent of dissection involvement. Among these, Stanford type A dissection originates in the ascending aorta and extends distally; it is the most critical subtype with the highest mortality rate, necessitating prompt surgical intervention involving replacement of the ascending aorta and aortic arch with a synthetic vascular graft.

For many years, China’s artificial blood vessel market has been dominated by foreign brands. Since 2020, imports of artificial blood vessels have been severely impacted by the pandemic, frequently resulting in shortages, incomplete product ranges, and even supply disruptions. In response to this situation, Jiangsu Biouder Life Technology Co., Ltd. independently developed and manufactured VASOLINE^®Artificial blood vessels have emerged.

On March 11, Jiangsu Biouder Life Technology Co., Ltd. (hereinafter referred to as “Biouder”)’s self-developed product VASOLINE^®Artificial Vascular Graft Launch Event Held at Shanghai Baolong Amari Hotel. Experienced cardiac surgeons, scholars, and industry investors from across China were invited to attend this press conference.

VCBeat provided a full live stream of the press conference; those who did not attend in person can scan our QR code to watch the replay.

As a key segment of the press conference, the Young Physicians’ Vascular Suturing Competition kicked off at 11:00 a.m. Six renowned cardiovascular surgery experts provided on-site instruction and commentary, demonstrating and guiding techniques for prosthetic vascular suturing. The training session aimed to provide a platform for academic exchange among young surgeons and to promote the advancement of their professional technical skills.

The press conference officially opened at 15:00.Dr. Du Guangwu, Founder and General Manager of VASOLINE, delivered the opening remarks, in which he stated:^®The advent of artificial blood vessels embodies the relentless efforts of all Utimda employees, and would not have been possible without the invaluable support of experts and researchers throughout the R&D, clinical trials, and commercialization processes. Moving forward, Utimda will continue to cultivate its presence in the medical device sector, providing Chinese patients with higher-quality products that are better tailored to the physiological anatomy of the Chinese population.

Sun Lizhong, President of Shanghai DeltaHealth HospitalVaseline was applied on-site.^®Release and Interpretation of Clinical Data on Artificial Blood Vessels: This Is Also VASOLINE^®Artificial blood vessels made their debut public release of nationwide multicenter clinical trial data. According to Director Sun: VASOLINE^®The 12-month postoperative survival rate for artificial blood vessels exceeds 95%, with all other evaluation metrics demonstrating non-inferiority to the control group. Clinical trials have confirmed that VASOLINE^®The safety and efficacy of artificial blood vessels have been fully validated, warranting their promotion for use in the post-market phase.

March 7, 2023Director Yang Yan, The First Affiliated Hospital of Xi'an Jiaotong UniversityCompleted VASOLINE^®Post-Market Implantation of Artificial Vessels: Director Yan Yang Provided a Brief Analysis of Surgical Techniques and Procedures at the Launch Event and Shared Insights on VASOLINE^®User Experience with Artificial Blood Vessels. He stated: VASOLINE^®Artificial blood vessels require no pre-clotting during surgery, offer excellent flexibility, exhibit minimal bleeding, and deliver performance comparable to imported products.

President Wu Xijie of the Cardiovascular Hospital of Xiamen University and Director Sun Qiang of the Third Provincial Hospital of ShandongAlso pioneered the clinical use of VASOLINE.^®Artificial Blood Vessels: During the case-sharing session, both Dean Wu and Director Sun expressed their views on VASOLINE^®Full recognition of artificial blood vessels, along with profound hopes for BioTissue.

After nearly a decade of effort by the Baiyouda R&D team, VASOLINE^®The artificial blood vessel received Class III medical device registration certification from the National Medical Products Administration in November 2022. Its market approval signifies that the first artificial blood vessel developed and manufactured by a domestic enterprise will break the monopoly held by European and American markets on similar products.Baiyouda will also take this opportunity to continuously cultivate the medical device field, aiming to benefit a broad patient population by striving to research, develop, and manufacture products that better align with the physiological anatomy of the Chinese population.

Jiangsu Biotech Life Science Co., Ltd.Founded in 2015, the company currently operates two production and R&D bases in Shanghai and Nantong, with a workforce of over 200 employees. In early 2022, construction commenced on the BioVeda Technology Park, located in the Nantong Beigaoxin Hi-Tech City and covering an area of 25,000 square meters. The first phase, comprising a 15,000-square-meter facility for artificial blood vessel production, began operations in December 2022. The company established its BioVeda R&D Center in Zhangjiang Med Valley, Shanghai, moving into the premises in October 2022. The center’s laboratories span 6,500 square meters, providing ample capacity for the R&D and production of a diverse range of products.

The company currently has more than 20 projects under development, covering multiple specialties including cardiovascular surgery, vascular surgery, cardiac surgery, and general surgery. Leveraging its technological platforms in polymer materials, biomaterials, and metal stent forming, the company is continuously launching high-quality products tailored to clinical needs, thereby benefiting a broad patient population.